An­oth­er day, an­oth­er $100M-plus biotech megaround as ra­dio­phar­ma­ceu­ti­cals’ pop­u­lar­i­ty grows

Af­ter get­ting start­ed in 2017 with a $25 mil­lion launch round, Fu­sion Phar­ma­ceu­ti­cals has bagged a $105 mil­lion mega round to ad­vance their work on new ra­dio­phar­ma­ceu­ti­cals, a field that has gar­nered new at­ten­tion as No­var­tis builds up its pipeline in the same are­na.

Their lead drug, now sit­ting on the thresh­old of Phase I, us­es an an­ti­body to guide al­pha-par­ti­cle emit­ting med­ical iso­topes to can­cer cells, cre­at­ing a kind of flash grenade of lo­cal­ized ra­di­a­tion to kill ma­lig­nant cells. And they’re tout­ing an in-house plat­form tech for link­ers they say will help pa­tients clear their bod­ies of med­ical iso­topes that aren’t bound to can­cer cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER